Target Name: CCNO
NCBI ID: G10309
Other Name(s): Cyclin-O | UNG2 | CCNU | Uracil-DNA glycosylase 2 | cyclin U | FLJ22422 | CCNO variant 1 | Cyclin domain containing | cyclin domain containing | UDG2 | CILD29 | cyclin O | Cyclin O, transcript variant 1 | CCNO_HUMAN | Cyclin U | Cyclin-like uracil-DNA glycosylase

CCNO: A Protein Targeted in Cancer and Cell Biology

Cyclin-O (CCNO) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell proliferation and has been implicated in many diseases, including cancer. Despite its importance, little is known about the biology of CCNO . In this article, we will explore the biology of CCNO and its potential as a drug target.

The Biology of CCNO

CCNO was first identified as a protein that was expressed in various tissues, including the brain, heart, and pancreas. It is a member of the T-cell signaling pathway, which is involved in regulating immune and inflammatory responses. CCNO is also involved in the regulation of cell cycle progression, which is a critical process for cell growth and division.

One of the key functions of CCNO is its role in regulating the length of the cell cycle. It does this by interacting with the protein cyclin D1 (CDK4), which is a key regulator of the cell cycle. CDK4 helps to ensure that the cell cycle proceeds in a timely and orderly manner, and it also helps to prevent the cell from getting stuck in certain stages of the cycle.

CCNO has also been shown to play a role in the regulation of cell differentiation. It helps to ensure that cells are able to transition from one type of cell to another, and this process is critical for the development and maintenance of tissues.

In addition to its role in cell biology, CCNO has also been implicated in the development of many diseases, including cancer. Studies have shown that CCNO is often overexpressed in various types of cancer, and that it is involved in the regulation of cell proliferation and survival. This suggests that CCNO may be a promising target for cancer therapies.

The potential of CCNO as a drug target

The potential of CCNO as a drug target is significant. Because it is involved in the regulation of cell biology and has been implicated in the development of many diseases, it may be a useful target for the development of new treatments.

One of the key advantages of CCNO as a drug target is its widespread expression in various tissues. This makes it less likely that any drug that targets it will have a significant impact on the entire body. In addition, because CCNO is involved in the regulation of cell biology, it is likely that any drug that targets it will have a more targeted and specific impact on cell behavior.

Another advantage of CCNO as a drug target is its involvement in the regulation of cell proliferation. This makes it a likely candidate for a drug that targets cell division and is effective in inhibiting the growth of cancer cells. In addition, because CCNO is involved in the regulation of cell differentiation, it may be a useful target for drugs that are effective in promoting the differentiation of cancer cells into healthier cells.

In conclusion, CCNO is a protein that is involved in the regulation of cell biology and has been implicated in the development of many diseases. As a result, it is a promising target for the development of new treatments. Further research is needed to fully understand the biology of CCNO and its potential as a drug target.

Protein Name: Cyclin O

Functions: Specifically required for generation of multiciliated cells, possibly by promoting a cell cycle state compatible with centriole amplification and maturation. Acts downstream of MCIDAS to promote mother centriole amplification and maturation in preparation for apical docking

More Common Targets

CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37